1,721,380 research outputs found
18F‐FDG PET/CT impact in grade 3B follicular lymphoma
No full text[F-18]-fluoro-D-glucose positron emission tomography/computed tomography (F-18-FDG PET/CT) is a non-invasive imaging tool that has a fundamental role in the management of FDG-avid lymphoma (also FL) in different settings, especially in the evaluation of treatment response and prognostication. The report by Barraclough et al. demonstrated that the treatment response evaluation by F-18-FDG PET/CT was a strong predictor of prognosis in grade 3B follicular lymphoma (G3BFL). Moreover, among semiquantitative baseline PET features, standardized uptake value (SUV) and TGL showed to be useful in predicting progression-free survival (PFS)
Metabolic tumor volume as prognostic factor in pediatric Hodgkin lymphoma: Dream or reality?
No full text
Is there a role for metabolic imaging in pediatric non-Hodgkin lymphoma?
No full text: Pediatric non-Hodgkin lymphoma (NHL) is an aggressive and heterogeneous malignancy with high rates of extranodal involvement. Accurate staging and response assessment are crucial, yet challenging. While [18F]FDG PET/CT is a cornerstone in adult NHL management, its role in pediatric cases remains under evaluation. A comprehensive review of the literature, international guidelines, and ongoing clinical trials was conducted, focusing on the diagnostic, prognostic, and therapeutic implications of [18F]FDG PET/CT in pediatric NHL. [18F]FDG PET/CT improves staging accuracy by detecting extranodal and bone marrow involvement more sensitively than conventional imaging. Its high negative predictive value supports its use in confirming complete metabolic response, potentially avoiding unnecessary biopsies. However, its positive predictive value is limited, cautioning against treatment escalation based solely on positive PET/CT results. Novel metabolic biomarkers such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) show promise for prognostic stratification but suffer from methodological variability and lack of standardization. Ongoing clinical trials aim to validate PET/CT's role in therapy response evaluation and optimize its clinical application. [18F]FDG PET/CT is a valuable imaging modality for pediatric NHL, particularly in FDG-avid subtypes. Despite promising results, broader clinical adoption requires standardized imaging protocols and prospective multicenter validation to establish robust diagnostic and prognostic utility
From 2015 to 2025: how ATA guidelines reshape nuclear medicine practice in thyroid cancer
No full textWhich role for [18F]FDG PET/CT in the “Recommendations for Updating Fever and Inflammation of Unknown Origin From a Modified Delphi Consensus Panel” by Wright et al.?
No full textContrast-enhanced 18F-FDG PET/CT to differentiate primary cardiac lymphoma from primary cardiac angiosarcoma
No full text
Performing an additional lateral decubitus PET/CT scan to resolve a respiratory motion artifact
No full textRespiratory motion artifacts may affect whole body 18F-FDG PET / CT scans interpretation, especially when lesions are localized between the liver and lung. We report a case of a patients affected by breast cancer who underwent PET/CT after therapy; a focal 18F-FDG uptake of not univocal interpretation was observed between liver and pleura. A subsequent acquisition on the right lateral decubitus showed the pleural location of lesion, thus improving the diagnostic accuracy of the PET/CT finding
18F-FDG PET/CT and primary hepatic MALT: a case series
No full textPrimary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma is an extremely rare disease and its glucidic metabolic behavior is not clear. We retrospectively analyzed five patients with histological diagnosis of primary hepatic MALT lymphoma who underwent twelve 18F-FDG PET/CT. All staging 18F-FDG PET/CT were positive showing 18F-FDG uptake (average SUVmax was 5.62 ± 1.6) at the corresponding liver lesion. 18F-FDG PET/CT also was useful in evaluating the complete metabolic response after chemotherapy in three patients and radiotherapy in two. Besides, in one patient 18F-FDG PET/CT detected disease relapse during follow-up. Despite the low number of patients, our case series shows the 18F-FDG avidity of hepatic MALT and the possible role of 18F-FDG PET/CT in the management of these patients, both for staging, treatment response evaluation and restaging. Further studies are needed to confirm our results
- …
